An innovative vaccine development company based on the frontier technology of immunology
Location: China
Investors 2
| Date | Name | Website |
| - | New Allian... | nac-capita... |
| 09.02.2022 | Matrix Par... | matrixpart... |
Mentions in press and media 1
| Date | Title | Description |
| 04.06.2021 | Advaccine Announces First Participants Dosed in Phase 2 Study of ADV110 Evaluating Respiratory Syncytial Virus (RSV) Vaccine Candidate in Australia | SUZHOU, China, June 4, 2021 /PRNewswire/ -- Advaccine Biopharmaceuticals ("Advaccine") announces that the first participants have been successfully dosed in its phase 2 study of ADV110, a respiratory syncytial virus (RSV) prophyla... |